Statement on the benefit assessment of trastuzumab deruxtecan (adenocarcinoma of the stomach or gastroesophageal junction, HER2-positive) of May 23, 2023

被引：0
|
作者：
不详
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2023年 / 61卷 / 07期
关键词：
D O I：
10.1055/a-2110-6846
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：938 / 942
页数：5
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
    Ishii, Takahiro
    Shitara, Kohei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1193 - 1201
  • [32] Efficacy and safety of sintilimab combined with trastuzumab and chemotherapy in HER2-positive advanced gastric or gastroesophageal junction cancer
    Liu, Zeyu
    Liu, Aina
    Li, Ming
    Xiang, Jinyu
    Yu, Guohua
    Sun, Ping
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [33] Efficacy of trastuzumab plus paclitaxel for HER2-positive gastroesophageal junction cancer that is refractory to S-1
    Setsuo Utsunomiya
    Takuya Kurimoto
    International Cancer Conference Journal, 2013, 2 (2) : 116 - 119
  • [34] Efficacy of trastuzumab plus paclitaxel for HER2-positive gastroesophageal junction cancer that is refractory to S-1
    Utsunomiya, Setsuo
    Kurimoto, Takuya
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2013, 2 (02): : 116 - 119
  • [35] Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma
    Yoon, Harry H.
    Lewis, Mark A.
    Foster, Nathan R.
    Sukov, William R.
    Khan, Maliha
    Sattler, Christopher A.
    Wiktor, Anne E.
    Wu, Tsung-Teh
    Jenkins, Robert B.
    Sinicrope, Frank A.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (07) : 1626 - 1631
  • [36] Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
    Yang, Jiangping
    Han, Jiaqi
    Zhang, Yalan
    Muhetaer, Muhelisa
    Chen, Nianyong
    Yan, Xi
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Exploratory biomarker analysis of trastuzumab deruxtecan in DESTINY-Gastric01, a randomized, phase 2, multicenter, open-label study in patients with HER2-positive or -low advanced gastric or gastroesophageal junction adenocarcinoma
    Shitara, K.
    Bang, Y.
    Iwasa, S.
    Sugimoto, N.
    Ryu, M.
    Sakai, D.
    Chung, H.
    Omuro, Y.
    Kawakami, H.
    Yabusaki, H.
    Sakamoto, Y.
    Nishina, T.
    Inaki, K.
    Kuwahara, Y.
    Suto, F.
    Sugihara, M.
    Saito, K.
    Kojima, A.
    Yamaguchi, K.
    ANNALS OF ONCOLOGY, 2021, 32 : S224 - S224
  • [38] Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Li, Ning
    Li, Zhi
    Fu, Qiang
    Zhang, Bin
    Zhang, Jian
    Wan, XiangBin
    Lu, Chaomin
    Wang, Jinbang
    Deng, Wenying
    Wei, Chen
    Ma, Yijie
    Bie, Liangyu
    Wang, Mengyu
    Luo, Suxia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [39] Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
    Antonarelli, G.
    Corti, C.
    Salimbeni, B. T.
    Tarantino, P.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Tolaney, S.
    Cortes, J.
    Curigliano, G.
    ESMO OPEN, 2023, 8 (04)
  • [40] The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with carcinomatosis
    Batista, Marta Vaz
    Perez-Garcia, Jose Manuel
    Garrigos, Laia
    Garcia-Saenz, Jose Angel
    Cortez, Patricia
    Racca, Fabricio
    Blanch, Salvador
    Ruiz-Borrego, Manuel
    Fernandez-Ortega, Adela
    Fernandez Abad, Maria
    Iranzo, Vega
    Gion, Maria
    Martrat, Griselda
    Alcala-Lopez, Daniel
    Perez-Escuredo, Jhudit
    Sampayo-Cordero, Miguel
    Llombart-Cussac, Antonio
    Braga, Sofia
    Cortes, Javier
    MED, 2025, 6 (01):
12345